94. Primary sclerosing cholangitis Clinical trials / Disease details
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03183570 (ClinicalTrials.gov) | November 8, 2017 | 8/5/2017 | Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT | Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 With [18F]FP-R01-MG-F2 With PET/CT | Idiopathic Pulmonary Fibrosis;Primary Sclerosing Cholangitis;Covid19 Pneumonia | Drug: [18F]FP-R01-MG-F2 | Stanford University | Pliant Therapeutics, Inc. | Recruiting | 18 Years | N/A | All | 30 | Early Phase 1 | United States |